ID   U-CH1
AC   CVCL_4988
SY   UCH-1; UCH1
DR   EFO; EFO_0004389
DR   ATCC; CRL-3217
DR   Cosmic; 2663857
DR   DepMap; ACH-002335
DR   DSMZ; ACC-748
DR   DSMZCellDive; ACC-748
DR   GDSC; 1503374
DR   GEO; GSM1673845
DR   GEO; GSM1673846
DR   PharmacoDB; UCH1_1626_2019
DR   PubChem_Cell_line; CVCL_4988
DR   Wikidata; Q54973610
RX   PubMed=11579460;
RX   PubMed=20461036;
RX   PubMed=21253487;
RX   PubMed=23325432;
RX   PubMed=26183925;
RX   PubMed=27102572;
RX   PubMed=28515451;
RX   PubMed=28606919;
RX   PubMed=28835717;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: ENCODE project common cell types; tier 3.
CC   Doubling time: ~1 week (Note=But can be significantly longer after recovery from liquid nitrogen freezing) (DSMZ=ACC-748); 2 days (PubMed=26183925); 9 days (Chordoma_Foundation).
CC   HLA typing: A*2 (Chordoma_Foundation).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Bone, sacrum; UBERON=UBERON_0003690.
ST   Source(s): ATCC; DSMZ; PubMed=21253487; PubMed=26183925; PubMed=27102572; PubMed=28835717
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D10S1248: 15
ST   D12S391: 17,22
ST   D13S317: 11,13
ST   D16S539: 12,13
ST   D18S51: 15
ST   D19S433: 14
ST   D1S1656: 16,16.3
ST   D21S11: 28,29
ST   D22S1045: 16
ST   D2S1338: 17,18
ST   D2S441: 12,14
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 9,12
ST   D8S1179: 10,15
ST   FGA: 20,21
ST   Penta D: 11
ST   Penta E: 7,10
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C129927; Sacral chordoma
DI   ORDO; Orphanet_178; Chordoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 31
RX   PubMed=11579460; DOI=10.1002/gcc.1184;
RA   Scheil S., Bruderlein S., Liehr T., Starke H., Herms J., Schulte M.,
RA   Moller P.;
RT   "Genome-wide analysis of sixteen chordomas by comparative genomic
RT   hybridization and cytogenetics of the first human chordoma cell line,
RT   U-CH1.";
RL   Genes Chromosomes Cancer 32:203-211(2001).
RX   PubMed=20461036; DOI=10.1097/BRS.0b013e3181c2a8b0;
RA   Yang C., Hornicek F.J., Wood K.B., Schwab J.H., Choy E., Iafrate A.J.,
RA   Rosenberg A.E., Nielsen G.P., Xavier R.J., Mankin H.J., Duan Z.-F.;
RT   "Characterization and analysis of human chordoma cell lines.";
RL   Spine 35:1257-1264(2010).
RX   PubMed=21253487; DOI=10.1155/2010/630129;
RA   Bruderlein S., Sommer J.B., Meltzer P.S., Li S., Osada T., Ng D.,
RA   Moller P., Alcorta D.A., Kelley M.J.;
RT   "Molecular characterization of putative chordoma cell lines.";
RL   Sarcoma 2010:630129.1-630129.14(2010).
RX   PubMed=23325432; DOI=10.1101/gr.147942.112;
RA   Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E.,
RA   Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A.,
RA   Crawford G.E., Absher D.M., Wold B.J., Myers R.M.;
RT   "Dynamic DNA methylation across diverse human cell lines and
RT   tissues.";
RL   Genome Res. 23:555-567(2013).
RX   PubMed=26183925; DOI=10.1158/0008-5472.CAN-14-3270;
RA   von Witzleben A., Goerttler L.T., Marienfeld R., Barth H., Lechel A.,
RA   Mellert K., Bohm M., Kornmann M., Mayer-Steinacker R., von Baer A.,
RA   Schultheiss M., Flanagan A.M., Moller P., Bruderlein S., Barth T.F.E.;
RT   "Preclinical characterization of novel chordoma cell systems and their
RT   targeting by pharmocological inhibitors of the CDK4/6 cell-cycle
RT   pathway.";
RL   Cancer Res. 75:3823-3831(2015).
RX   PubMed=27102572; DOI=10.1002/path.4729;
RA   Scheipl S., Barnard M., Cottone L., Jorgensen M., Drewry D.H.,
RA   Zuercher W.J., Turlais F., Ye H., Leite A.P., Smith J.A., Leithner A.,
RA   Moller P., Bruderlein S., Guppy N., Amary F., Tirabosco R.,
RA   Strauss S.J., Pillay N., Flanagan A.M.;
RT   "EGFR inhibitors identified as a potential treatment for chordoma in a
RT   focused compound screen.";
RL   J. Pathol. 239:320-334(2016).
RX   PubMed=28515451; DOI=10.1038/s41598-017-02174-5;
RA   Jager D., Barth T.F.E., Bruderlein S., Scheuerle A., Rinner B.,
RA   von Witzleben A., Lechel A., Meyer P., Mayer-Steinacker R., Baer A.V.,
RA   Schultheiss M., Wirtz C.R., Moller P., Mellert K.;
RT   "HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and
RT   sacral chordomas.";
RL   Sci. Rep. 7:2032-2032(2017).
RX   PubMed=28606919; DOI=10.1158/1078-0432.CCR-17-0177;
RA   Chen H., Garbutt C.C., Spentzos D., Choy E., Hornicek F.J.,
RA   Duan Z.-F.;
RT   "Expression and therapeutic potential of SOX9 in chordoma.";
RL   Clin. Cancer Res. 23:5176-5186(2017).
RX   PubMed=28835717; DOI=10.1038/s41598-017-10044-3;
RA   Bosotti R., Magnaghi P., Di Bella S., Cozzi L., Cusi C., Bozzi F.,
RA   Beltrami N., Carapezza G., Ballinari D., Amboldi N., Lupi R.,
RA   Somaschini A., Raddrizzani L., Salom B., Galvani A., Stacchiotti S.,
RA   Tamborini E., Isacchi A.;
RT   "Establishment and genomic characterization of the new chordoma cell
RT   line Chor-IN-1.";
RL   Sci. Rep. 7:9226-9226(2017).